Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639750 | 0.92 | TSHR (0.42) | TSHRALDH1A1THRBDNM1 | |
| SCHEMBL5145378 | 0.89 | TSHR (0.46) | TSHRLMNATHRBDNM1 | |
| SCHEMBL3120664 | 0.89 | TSHR (0.46) | TSHRLMNATHRBDNM1 | |
| SCHEMBL5648168 | 0.89 | TSHR (0.46) | TSHRLMNATHRBDNM1 | |
| SCHEMBL25378343 | 0.89 | TSHR (0.46) | TSHRLMNATHRBDNM1 | |
| SCHEMBL181617 | 0.81 | — | — | |
| SCHEMBL3027388 | 0.80 | TSHR (0.39) | TSHRALDH1A1LMNATHRBDNM1 | |
| SCHEMBL4534104 | 0.80 | TSHR (0.39) | TSHRALDH1A1LMNATHRBDNM1 | |
| SCHEMBL15900023 | 0.78 | DNM1 (0.42) | TSHRALDH1A1THRBDNM1 | |
| SCHEMBL3246343 | 0.74 | TSHR (0.35) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1692112-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1622878-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1622883-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1622613-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2008032060-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| EP-1558589-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070232597-A1 | Compounds, Compositions, and Methods | CYTOKINETICS, INC. | 2007-10-04 | — | — | US | claimed |
| US-7271167-B2 | 2-(Imidazol-1-ylalkyl)-3H-quinazolin-4-one derivatives; mitotic kinesin KSP inhibitors; anticarcinogenic, antiinflammatory, and antiproliferative agents | CYTOKINETICS, INC. (US) | 2007-09-18 | — | — | US | claimed |
| WO-2005041888-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| WO-2005013888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2004103282-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004091547-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004032879-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-0433805-A1 | N-Substituted 3-cyano-4-phenyl-pyrroles | BAYER AG (DE) | 1991-06-26 | — | — | EP | claimed |
| US-4914122-A | CONTROLLING PLANT DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-04-03 | — | — | US | claimed |
| EP-0327977-A1 | 1-Aminomethyl-3-(2,4-difluor-3-chlorphenyl)-4-cyanopyrroles | BAYER AG (DE) | 1989-08-16 | — | — | EP | claimed |
| EP-0327987-A1 | 1-Aminomethyl-3-(2-fluoro-3-chlorophenyl)-4-cyano-pyrrole derivatives | BAYER AG (DE) | 1989-08-16 | — | — | EP | claimed |
| EP-0281731-A2 | 1-Aminomethyl-3-aryl-4-cyano-pyrroles | BAYER AG (DE) | 1988-09-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | TSHR 4402/4885ALDH1A1 3816/4885LMNA 1960/4885 |
| US-20070232597-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | TSHR 4738/4885ALDH1A1 2465/4885LMNA 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.